LIB Therapeutics announced that the US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA ...
Last year marked an all-time record of 18 Food and Drug Administration (FDA) biosimilar approvals, bringing the total number ...
Alvotech and Teva Pharmaceuticals (“Teva”) announced that the U.S. Food and Drug Administration (FDA) has accepted for review ...
Alvotech and Teva Pharmaceuticals announced the US Food and Drug Administration (FDA) has accepted for review a Biologics ...
So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval ...
Merck (MRK) announced the FDA has accepted for priority review a new supplemental Biologics License Application seeking approval for keytruda – ...
In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg. Teva also ...
Alvotech and Teva Pharmaceuticals announced that the U.S. FDA has accepted for review a Biologics License Application for AVT06, a proposed biosimilar to Eylea® (aflibercept), which treats eye ...
Alvotech and Teva Pharmaceuticals have announced the FDA's acceptance of their Biologics License Application for AVT06, a proposed biosimilar to Eylea®, aimed at treating various eye disorders ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results